Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + zoledronic acid
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of two drugs: - **Docetaxel** is a taxane-class chemotherapeutic agent that inhibits cell division by stabilizing microtubules, thereby preventing their depolymerization. It is primarily used as an antineoplastic agent in various cancers. - **Zoledronic acid** is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. It is used to prevent skeletal-related events (SREs) in patients with bone metastases and has demonstrated some direct antitumor effects. The combination has been studied for potential additive or synergistic effects in cancer treatment, particularly for advanced prostate cancer and non-small-cell lung cancer (NSCLC) with bone metastases. Clinical trials have evaluated this regimen for its impact on survival, progression-free survival, and reduction of skeletal-related events[1][2][3].
- Brand names
- TaxotereZometa
- Other names
- docetaxel + zoledronicdocetaxel plus zoledronic aciddocetaxel and zoledronic acid
02
Targets
FDPS (Farnesyl pyrophosphate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + zoledronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + zoledronic acid.